The promising results obtained by clinical trials using Rimonabant to tackle visceral obesity and related disorders recently promoted a remarkable impulse to carry out detailed investigations into the mechanisms of action of endocannabinoids in regulating food intake and energy metabolism. The endocannabinoid system has been known for many years to play an important role in the modulation of the neuronal pathways mediating the rewarding properties of food. However, in the last few years, with the advanced understanding of the crucial role of the hypothalamic neuronal network in the regulation of appetite, several studies have also directed attention to the orexigenic role of the endocannabinoid system, substantiating the well known appetite stimulating properties of derivatives of Cannabis sativa. Furthermore, the last 2 years have seen a number of relevant publications emphasizing the role of endocannabinoids as significant players in various peripheral metabolic processes. To date, the roles of the endocannabinoid system in influencing energy metabolism have proved to be more complex than was formerly believed. However, the diverse ability to modulate both central and peripheral processes highlights the pivotal involvement of the endocannabinoid system in the control of metabolic processes. This review describes the roles of endocannabinoids and the cannabinoid type 1 receptor (CB1) in the control of energy balance.
Introduction
Associated with the psychotropic properties, orexigenic activities were attributed to the vegetal derivatives of Cannabis sativa. Ancient traditions of various ethnic origins reported that extracts of plants containing cannabinoids could be of therapeutic use to promote appetite. 1 Such historical anecdotal reports have provided the rationale for introducing the component of C. sativa, D
9
-tetrahydrocannabinol (THC) (known as Dronabinol) in clinical trials, in order to stimulate appetite and to reduce the weight loss in cachectic states associated with AIDS or malignant tumors. 2, 3 This relatively recent clinical development in the therapeutic use of THC was anticipated by a long series of studies carried out in animals and humans to investigate the putative orexigenic effects of THC or Cannabis extracts. 1 
Endocannabinoid system and mesolimbic system
Although these pioneer studies were largely heterogeneous in the experimental models and sometimes different in the conclusions due to the different dosages, route of administration and purity of the substances used, they all strongly reinforced the hypothesis that marijuana and its derivates stimulate food intake. In particular, studies conducted in humans confirmed the anecdotal observation that Cannabis derivatives mainly stimulate the intake of palatable food. 1 The whole body of these studies paved the way to the development of drugs aimed at antagonizing cannabinoid type 1 receptor (CB1) in order to investigate the putative effect of the endocannabinoid system on feeding behaviour in detail. The first specific CB1 antagonist (SR141716, now called Rimonabant) was generated in the laboratories of sanofi-aventis research. 4 Initially, the effects of this compound were studied, in different behavioral models of ingestion of palatable food, in rats, mice and marmosets. 5, 6 Interestingly, in rats, SR141716 reduced spontaneous sucrose intake in both solid and liquid forms at doses which did not alter regular food intake in the choice situation. 5 Moreover, ethanol ingestion in rats and C57BL/6 mice. 7, 6 Altogether, these results strongly supported the notion that an endogenous cannabinoid tone could operate to intensify the appetitive value of sucrose and ethanol, probably modulating mesolimbic reward systems. 8, 9 In such a context, it was shown that endocannabinoids may interact with the dopaminergic pathway in inducing hyperphagia in rats when injected into the nucleus accumbens. 8 A functional cross-talk between the endocannabinoid and the endogenous opioid system was also proposed, because Rimonabant and naloxone, an opioid receptor antagonist, were shown to act synergistically in the inhibition of food intake. 10 
Endocannabinoid system and hypothalamus
The studies on the rewarding properties of endocannabinoids at the level of mesolimbic system paved the way to the initial understanding of the orexigenic activity of CB1 receptors. However, this aspect was still far from giving the complete picture of the sites where the endocannabinoid system might regulate food intake. In the last few years, endocannabinoids and CB1 have been identified as important players in the hypothalamic neuronal network regulating appetite and food intake. 11 For many years, it has been known that the injection of THC directly into the ventromedial and/or lateral hypothalamus induces a strong impulse in food intake. 12 Interestingly, also endocannabinoids, such as anandamide, induced significant hyperphagia when administered into the ventromedial hypothalamus. 13 In the same study, the authors showed that pretreatment with the CB1 antagonist SR141716 prior to anandamide injection led to an attenuation of the endocannabinoidinduced hyperphagia, indicating that the effect of anandamide at hypothalamic level was through a specific CB1 activation. 13 Fasting and feeding are associated with high and low levels of endocannabinoids in the hypothalamus, respectively. 14 Therefore, it seems that endocannabinoids are important sensors of acute changes of the nutritional state. Moreover, CB1 is expressed in key hypothalamic peptidergic systems of appetite regulation, including those producing corticotropin-releasing hormone (CRH) in the paraventricular nucleus, cocaine-amphetamine-regulated transcript (CART) in the dorsomedial nucleus and melanin-concentrating hormone (MCH) and orexins in the lateral hypothalamus-perifornical region. 15 A possible inhibition of anorexic signals conveyed by CRH and POMC neurons and a putative sensitization of the orexigenic signal conveyed by orexins was recently proposed. 16 Moreover, CB1 À/À mice (animals lacking CB1 expression) have increased CRH expression in the paraventricular nuclei and reduced CART expression in the dorsomedial and lateral hypothalamus, 15 indicating that genetic impairment of the endocannabinoid signal may affect the pattern of gene expression of peptides involved in food intake regulation. Importantly, recent data show that functional activation of CB1 strongly potentiates orexin Astimulated intracellular pathway mediated by Orexin 1 receptors. 17 Moreover, the recent finding that SR141716
and a-MSH (melanocyte-stimulating hormone) contribute in a synergistic fashion to reduce food intake also makes it possible to include the interaction of these two systems in the increasing numbers of hypothalamic mechanisms regulating food intake. 18 Owing to the important role of neuropeptide Y (NPY) in the transmission of orexigenic signals, it was surprising not to find any expression of CB1 in NPY positive neurons 15. The lack of a direct cross-talk between endocannabinoid system and NPY-ergic neurons is also confirmed by the fact that no altered levels of NPY expression have been found in CB1
À/À mice. In addition, the CB1 antagonist SR 141716 still inhibits starvation-induced hyperphagia in NPY À/À mice. 19 These data seem to indicate that, although NPY represents one of the most powerful orexigenic peptides, CB1 conveys signals independently of NPY.
The mechanisms of action of the endocannabinoid system at the hypothalamic level still need to be fully elucidated. Recently, Di et al. 20 described a retrograde CB1-mediated action of endocannabinoids to decrease presynaptic glutamatergic transmission onto CRH-producing neurons. However, a tight interaction between axonal processes and postsynaptic targets as recently proposed for leptin 21 might represent the mechanism of endocannabinoid action. Leptin, a satiety factor, is known to play a pivotal role in food intake modulation by the downregulation of the expression of orexigenic hypothalamic peptides, such as NPY, orexin and MCH. 11 An elegant study by Di Marzo et al. 19 clearly showed a strong interaction between the endocannabinoid system and hypothalamic networks governing food intake. In obese genetic rodent models lacking leptin or leptin receptors, hypothalamic endocannabinoid levels are strongly increased, indicating an inhibitory action of leptin on endocannabinoid signaling. 19 Importantly, normal levels of endocannabinoids were observed in ob/ob mice (animals deprived of functionally active leptin) after intravenous administration of leptin, indicating that a direct negative control is exerted by leptin on the endocannabinoid production. 19 These relevant findings make it possible to hypothesize that chronic diseases, such as obesity, might be associated with an overactivation of the endocannabinoid system. The ghrelinergic pathway, whose activation leads to a sustained increase in food intake, 22 was also shown to interact with endocannabinoid signaling. Recent data showed that peripheral administration of Rimonabant prevents the food intake-inducing effects of ghrelin injected into intraperiventricular nucleus. 23 These results seem to indicate that the endocannabinoid system activation is essential to fully display ghrelin-induced hyperphagia. All together the whole body of these data show that endocannabinoids interact strongly and extensively with the hypothalamic peptidergic circuits involved in food intake.
The endocannabinoid system should thus be definitively acknowledged as a key player in the modulation of orexigenic signals.
Endocannabinoid system and peripheral organs
The data described above indicate that endocannabinoids control food intake by modulating the activity of several brain regions. The brain has for a long time been the only recognized site of action of the endocannabinoid system in the regulation of energy balance. However, already in 1998 a publication by Colombo et al. showed that the treatment of rats with Rimonabant for 14 days was able to induce a body weight loss persisting well beyond the temporary effect of the drug on food intake (5 days). Thus, the authors hypothesized that the initial reduction of body weight was due to the severe anorexia induced by Rimonabant, whereas the longer lasting effect of Rimonabant on body weight might be caused by an increase in energy expenditure. 24 This study offered the first published evidence of a putative peripheral effect on the regulation of energy balance by endogenous CB1 activation. Later, the presence of CB1 receptors in vagal afferent neurons expressing the satiety hormone cholecystokinin (CCK) was described. These neurons project to the stomach and duodenum. The expression of CB1 in the vagal afferent neurons was shown to be increased by food deprivation and decreased by a following refeeding period. These effects can be blocked by CCK antagonists and mimicked by administration of CCK itself. 25 Therefore, the activation of CB1 on nerve terminals innervating the gastrointestinal tract may be involved in mediating satiety signals originating in the gut and the endocannabinoid system may also influence food intake by a gastroduodenal cross-talk with CCK signaling. 25 In support of this hypothesis, endocannabinoid levels in the gastrointestinal tract are regulated by the feeding state. In fact, starvation induces a seven-fold increase in the levels of anandamide in the small intestine, an effect that is reversed by refeeding. 26 Moreover, the mucosal tissue of the stomach fundus expresses CB1 receptors. 27 Considering that ghrelin is synthesized in the same portion of the organ, 22 a functional interaction between endocannabinoid and ghrelinergic systems might be hypothesized in the gastrointestinal tract too.
In the last few years, two experimental models have substantially helped to improve our knowledge concerning the peripheral metabolic functions of the endocannabinoid system: on one hand the generation of mutant mice lacking CB1 receptor and on the other hand the use of diets inducing obesity in these genetically mutated rodents.
We recently showed that CB1 À/À mice are leaner and lighter than control wild-type littermates. As demonstrated by nuclear magnetic resonance, the body weight reduction is due to a significant decrease in fat mass. 'Pair-feeding' experiments on adult CB1 À/À and control mice showed that the leaner phenotype is partially due to a food intakeindependent mechanism, likely related to altered metabolic processes. 15 Similar results were independently obtained by the sanofi-aventis group. 28 Importantly, the authors found that CB1 À/À are resistant to diet-induced obesity (DIO) and, under these conditions, display a metabolic profile strongly improved as compared to wild-type controls. In particular, the insulin resistance normally occurring in high-fat diet-fed mice is not present in CB1 À/À mice. These effects can only partially be attributed to a reduction of food intake. In fact, the feeding efficiency of CB1 À/À mice remained low as compared to wild-type animals. Interestingly, the metabolic effects of the endocannabinoid system were recently confirmed in rodents treated with different CB1 antagonists (such as Rimonabant or AM251). In DIO mice, both Rimonabant and AM251 induce a transient anorectic effect followed by a significant and more sustained reduction in body weight, due to a decrease in body fat mass. 29, 30 These relevant findings have greatly widened our perspectives in understanding the antiobesity mechanisms of action of CB1 antagonists. Indeed, these drugs are likely able to decrease fat accumulation initially by targeting neuronal sites and thereafter by modulating peripheral metabolic regulation.
Endocannabinoids and white adipose tissue
Searching for the putative peripheral target/s of endocannabinoid system activation, white adipose tissue was another logical candidate in addition to the gastroinetstinal tract in which to look for the expression of CB1 and eventually for production of endocannabinoids. Indeed, CB1 is expressed in mature adipocytes, 15 whereas preadipocytes contain lower levels of the receptor. 31 Moreover, adipose tissue derived from obese mice expresses higher levels of CB1 as compared to lean controls, 31 confirming the notion that an overactivation of the endocannabinoid system is associated with obesity. Activation of CB1 receptors stimulates lipoprotein lipase activity in cultured adipocytes and Rimonabant reverses this effect. 15 Importantly, Rimonabant can directly stimulate adiponectin release from adipocytes in vitro. 31 Very recently, increased plasmatic adiponectin levels were observed in DIO mice after a long treatment period of Rimonabant (10 weeks). 32 Notably, the antiobesity effect of Rimonabant was equivalent (both in term of time course and maximum effect) to that achieved by switching obese mice to standard diet for 10 weeks. Nevertheless, as expected, after a short period of a reduction of food intake, in the following part of the experiment the energy intake in the Rimonabanttreated animal group was equivalent to that in the high-fat diet group, and significantly higher than in the group receiving standard diet. 32 This experiment confirmed the notion that Rimonabant displays a long-lasting effect on body weight, which is partially independent of food intake. Although the mice treated with Rimonabant were main-tained on high-fat diet with elevated energy intake throughout the study period, favourable changes in the plasma lipid profile were observed after the treatment. In particular, a normalization of triglycerides and LDL cholesterol and an elevation of HDL cholesterol were observed. The authors hypothesized that the increase in serum adiponectin levels following the treatment is responsible for this general amelioration of the lipid profile. 32 Adiponectin, which is the most abundant gene product in adipose tissue, circulates in large amounts in plasma. 33, 34 This adipokine displays antiatherogenic and antidiabetic properties and its increase is associated with improvement of insulin sensitivity. 33, 34 In the liver, adiponectin decreases hepatic glucose production and regulates free fatty acid metabolism, by suppressing lipogenesis and by activating free fatty acid oxidation. Moreover, adiponectin levels are directly correlated with HDL levels and inversely correlated with LDL. 33, 34 Adiponectin circulating levels are significantly reduced in obese subjects, but also in patients with diseases associated with obesity, such as type 2 diabetes, polycystic ovary syndrome and coronary artery disease. 33, 34 In conclusion, we can summarize that cannabinoid antagonists might have a protective role in the development of obesity by directly targeting adipose tissue functions.
Endocannabinoids and muscles
As mentioned above, the search for putative targets of endocannabinoid action at peripheral metabolic sites recently became a central goal of many laboratories and it is not surprising that in the last few months a series of reports brought other candidate organs into play, such as brown adipose tissue and the skeletal muscles. Prolonged treatment of DIO mice with the CB1 antagonist AM251 increased uncoupling protein-1 (UCP-1) and uncoupling protein-3 (UCP-3) mRNA levels in brown adipose tissue making it possible to hypothesize that blocking the endocannabinoid system may increase thermogenesis. 35 It is important to note that adiponectin is also able to increase UCP-1 at the level of brown adipose tissue. On the other hand, when compared to CB1 þ / þ , CB1 À/À mice showed a difference, although not significant, in energy expenditure. 15 Very recently, a 7-day treatment with Rimonabant caused a strong increment in basal oxygen consumption as compared to vehicle-treated animals and a significant increase in glucose uptake in isolated soleus muscle preparations. 36 Therefore, Rimonabant may directly impact energy expenditure at the skeletal muscle level suggesting that the antiobesity effect of Rimonabant can also be due to the activation of thermogenesis. Moreover, the Rimonabant-mediated increase in glucose uptake in the soleus muscle may contribute to the improvement in the glycemic profile observed in other studies.
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CB1 is also expressed at the hepatic level and its activation produces a vasoactive function. 37 In this rapidly changing scenario, we cannot, at present, exclude a putative effect of cannabinoids at the level of the liver, which is another key organ in the regulation of metabolic processes.
Conclusions
From an ancient tradition that attributed orexigenic properties to the derivatives of marijuana to the development of a novel class of drugs able to fight obesity, a long story is approaching its conclusion. Old and new data demonstrate that the endocannabinoid system should now be recognized as a new crucial player in energy balance control. The system is likely overactivated in conditions such as obesity as demonstrated by the increased levels of endocannabinoids in the hypothalamus and by the CB1 overexpression in adipose tissue derived from obese rodents. Therefore, when chronically and pathologically activated, the endocannabinoid system probably induces a permanent hyperphagia, leads to fat accumulation and contributes to the development of an obese phenotype. The pharmacological blockade of CB1 might normalize the imbalance induced by the overactivation of the endocannabinoid system. Therefore, CB1 antagonists acting on various target organs distributed at central and peripheral levels might represent novel and interesting therapeutic tools with which to tackle obesity and related diseases.
